摘要
目的观察含奥沙利铂联合方案治疗进展期结直肠癌的临床疗效及毒副反应。方法经病理检查确诊的36例进展期结直肠癌患者分为A、B两组,分别予FOLFOX4(奥沙利铂、氟尿嘧啶和亚叶酸钙)方案及XELOX(奥沙利铂和卡培他滨)方案化疗,按WHO标准评价客观疗效和毒副反应。结果入组36例均可评价疗效。A组24例,无CR者,PR9例,近期客观有效率37.5%,中位疾病进展时间(TTP)为7.0个月;B组12例,CR1例,PR4例,近期客观有效率41.7%,中位TTP为7.1个月,两组近期有效率无统计学差异。结论与标准的FOLFOX4方案比较,XELOX方案治疗进展期结直肠癌疗效确切,毒副反应轻,尤其对于一般情况欠佳的患者耐受性好。
Objective：To evaluate the efficacy and toxicity of combination therapy based on oxaliplatin in patients with advanced colorectal cancer. Methods：36 cases with advanced colorectal cancer were divided into group A/B and treated with FOLFOX4 （oxaliplatin plus LV5 FU2 ）/XELOX（ oxaliplatin plus capecitabine） regimen respectively. Results：All 36 cases were available for objective response. The overall response rate was 37.5% （ CR 0 ,PR 9） in group A of 24 cases and 41.7% （ CR 1 ,PR 4） in group B of 12 cases. The median TTP of group A and B are 7. 0 months and 7. 1 months respectively. Conclusion：As same as FOLFOX4 regimen, XELOX is tolerable and clinically active in advanced colorectal cancer.
出处
《临床肿瘤学杂志》
CAS
2005年第5期507-509,共3页
Chinese Clinical Oncology
关键词
奥沙利铂
卡培他滨
结直肠癌/进展期
化疗
Oxaliplatin
Capecitabine
Colorectal Cancer/advanced stage
Chemotherapy
